<< Hospital-insurer tug of war leaves patients in middle | Health policy research roundup >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

First-quarter fiscal 2010 results announced by Biomet

Published on October 9, 2009 at 11:14 AM · No Comments

Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2009.

  • Net sales increased 4% (7% constant currency) to $630 million, with 9% growth in the U.S.
  • Reconstructive sales, excluding dental, increased 5% (9% constant currency) worldwide, with 10% U.S. growth
  • Knee sales increased 6% (10% constant currency) worldwide, with U.S. growth of 9%
  • Hip sales increased 2% (6% constant currency) worldwide, with 4% U.S. growth
  • Extremity sales increased 18% (23% constant currency) worldwide, and increased 39% in the U.S.
  • Spine sales increased 15% (17% constant currency) worldwide, with 15% U.S. growth

Net sales increased 4% during the first fiscal quarter ended August 31, 2009, to $630.1 million from $607.0 million for the first quarter of fiscal year 2009. Excluding the impact of foreign currency, net sales increased 7% during the first quarter.

U.S. sales increased 9% to $400.2 million during the quarter; Europe sales of $154.8 million decreased 9% (increased 3% constant currency); and International (primarily Canada, South America, Mexico and the Pacific Rim) sales increased 9% to $75.1 million (13% constant currency). Excluding dental and the impact of foreign currency, net sales during the first quarter of fiscal 2010 increased 9% worldwide, 10% in the U.S., 7% in Europe, and 10% for International.

During the first quarter of fiscal 2010, Biomet reported $113.0 million of special items (pre-tax), including purchase accounting charges of $98.4 million. The purchase accounting charges primarily relate to amortization expense for established intangible assets and depreciation expense as a result of the step-up of property to fair value. The remaining $14.6 million of special items included costs primarily related to the Company’s Operational Improvement Program and $5.2 million of stock compensation expense. A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website: www.biomet.com

Source Biomet, Inc.

Posted in:

Tags: , , , , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading